Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent?s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co.,
|Shares Outstanding||EPS||-0.39||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-92.74%||Sales Growth - Q/Q||15.52%||P/E||-1.95|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-114.32%||ROE||-391.69%||ROI||-243.81%|
|Current Ratio||1.67||Quick Ratio||Long Term Debt/Equity||0.46||Debt Ratio||1.82|
|Gross Margin||Operating Margin||-1843.19%||Net Profit Margin||-1925.98%||Dividend Payout Ratio|
|Cash From Financing Activities||1.67 M||Cash From Investing Activities||-3.62 M||Cash From Operating Activities||-15.82 M||Gross Profit|
|Net Profit||-10.87 M||Operating Profit||-10.15 M||Total Assets||50 M||Total Current Assets||44.42 M|
|Total Current Liabilities||26.55 M||Total Debt||18.02 M||Total Liabilities||35.41 M||Total Revenue||130 K|
|High 52 week||3.48||Low 52 week||0.59||Last close||0.66||Last change||5.76%|
|RSI||54.47||Average true range||0.05||Beta||1.05||Volume||244.22 K|
|Simple moving average 20 days||-16.37%||Simple moving average 50 days||-53.57%||Simple moving average 200 days||-69.38%|
|Performance Week||6.92%||Performance Month||-61.79%||Performance Quart||-66.95%||Performance Half||-72.11%|
|Performance Year||-76.89%||Performance Year-to-date||-58.69%||Volatility daily||20.49%||Volatility weekly||45.82%|
|Volatility monthly||93.91%||Volatility yearly||325.31%||Relative Volume||297.41%||Average Volume||3.32 M|
|New High||New Low|
2020-06-02 11:41:03 | FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
2020-06-02 04:00:52 | Aveo’s Tivozanib Gets FDA Nod For New Drug Application To Treat Kidney Cancer
2020-06-01 08:52:12 | Implied Volatility Surging for AVEO Pharmaceuticals AVEO Stock Options
2020-05-30 11:31:03 | Why Is AVEO AVEO Up 24.8% Since Last Earnings Report?
2020-05-29 07:05:00 | AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® tivozanib in Combination with IMFINZI® durvalumab in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2
2020-05-27 16:05:00 | AVEO Announces Change to Virtual Annual Meeting of Stockholders
2020-05-12 08:50:12 | Why You Shouldn't Bet Against AVEO Pharmaceuticals AVEO Stock
2020-04-30 09:55:01 | AVEO Pharmaceuticals AVEO Reports Q1 Loss, Lags Revenue Estimates
2020-04-30 07:00:00 | AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update
2020-04-15 11:30:03 | AVEO AVEO Up 39.9% Since Last Earnings Report: Can It Continue?
2020-03-30 11:54:03 | AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic
2020-03-17 11:52:03 | AVEO Pharmaceuticals AVEO Q4 Earnings Beat & Sales Miss
2020-03-16 17:25:09 | AVEO Pharmaceuticals AVEO Reports Q4 Loss, Lags Revenue Estimates
2020-03-16 16:05:00 | AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update
2020-02-26 12:00:05 | What Makes AVEO AVEO a New Buy Stock
2020-02-19 09:08:00 | AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split
2020-01-28 11:14:28 | AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
2020-01-06 07:00:00 | AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer
2019-12-20 17:34:42 | Is AVEO Pharmaceuticals, Inc. AVEO Going To Burn These Hedge Funds ?
2019-12-20 10:25:03 | Implied Volatility Surging for AVEO Pharmaceuticals AVEO Stock Options
2019-12-12 11:30:04 | Why Is AVEO AVEO Down 0.1% Since Last Earnings Report?
2019-11-26 07:00:00 | AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-11-19 07:00:00 | AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors
2019-11-15 08:57:01 | Sarepta SRPT Stock Down Despite New $48M Gene Therapy Deal
2019-11-13 13:14:06 | AVEO Pharmaceuticals AVEO Q3 Earnings & Revenues Top Mark
2019-11-12 07:00:00 | AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update
2019-11-08 10:08:03 | Spectrum Pharma's SPPI Q3 Loss Narrows, Focus on Rolontis
2019-11-08 10:00:03 | Global Blood's GBT Q3 Loss Widens, Voxelotor in Focus
2019-11-07 11:08:04 | Zoetis ZTS Beats on Earnings in Q3, Reports In-Line Sales
2019-11-07 11:05:04 | Horizon Therapeutics' HZNP Q3 Earnings Beat Estimates
2019-11-07 07:00:00 | AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
2019-11-06 11:00:04 | Ultragenyx RARE Reports Wider-Than-Expected Loss in Q3
2019-11-06 10:34:03 | Intercept ICPT Earnings and Sales Miss Estimates in Q3
2019-11-04 07:00:00 | AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma
2019-11-01 10:30:02 | AVEO Pharmaceuticals AVEO Earnings Expected to Grow: Should You Buy?
2019-10-22 09:32:01 | AVEO Sees Hammer Chart Pattern: Time to Buy?
2019-10-17 08:58:12 | Reata RETA Jumps: Stock Rises 5. 6%
2019-10-16 09:00:01 | AVEO AVEO Upgraded to Strong Buy: What Does It Mean for the Stock?
2019-09-30 07:00:00 | AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® tivozanib in Combination with IMFINZI® durvalumab in Previously Untreated Metastatic Hepatocellular Carcinoma